TSW
CPRX

Three Seasons Wealth’s Catalyst Pharmaceutical CPRX Stock Holding History

Three Seasons Wealth’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,324
Closed -$493K – 118
2025
Q1 		$493K Buy
+20,324
New +$458K 0.24% 63

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Three Seasons Wealth's CPRX Position: Q2 2025 in Review

Three Seasons Wealth sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 20,324 shares — an estimated $493K sold.

Three Seasons Wealth first reported a position in CPRX in Q1 2025 and held it in 1 quarter. The position peaked at $493K in Q1 2025. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

  • Three Seasons Wealth reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Three Seasons Wealth sold 20,324 Catalyst Pharmaceutical shares in Q2 2025, an estimated $493K.
  • Three Seasons Wealth first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 1 quarter.
  • Three Seasons Wealth's Catalyst Pharmaceutical position peaked at $493K in Q1 2025.
  • 365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on Three Seasons Wealth's 13F filing for Q2 2025, filed 10 Jul 2025.